NEW JERSEY ALLIANCE FOR

CLINICAL AND TRANSLATIONAL SCIENCE

NEWS, EVENTS, and DEADLINES

September 15, 2022

Upcoming NJ ACTS, Rutgers & Princeton Events

2022 Request for Applications

NJ ACTS Career Development Scholar Program (KL2)

An important opportunity for early-stage faculty to be able to devote 80% effort* to their projects, receive research funding and have the support of the community.

RFA for Translational Scientist: an abbreviated description of the program with a full list of the eligibility requirements.

Scholar Program Description: a detailed overview of the NJ ACTS KL2 Program, including information on current and former KL2 Scholars and a listing of the KL2 Program's Academy of Mentors.

Proposal Guidance and Requirements: a listing of the required components of a KL2 Scholar application packet.

NJ ACTS KL2 Scholar Application: a fillable pdf to be submitted with the other required application materials.

Key Dates/Deadlines

Letter of Intent Due: October 3, 2022 at 5 p.m.

Full Application Due: November 1, 2022 at 5 p.m.

Interviews: December 2022/January 2023

Notification of Awards: February 1, 2023

Award Start Date: July 1, 2023

For more information, contact kl2njacts@rbhs.rutgers.edu

*Applicable to Institution

Upcoming I-Corps Events

Novus @ Rutgers Program

3-hour virtual workshop co-sponsored with Innovation Ventures which is designed to help individuals and teams of innovators shift their mindset from the science to the people it would benefit and help them form teams to advance their innovation forward.

Sept 16th

9:30am - 12:30pm

____________

Propelus I-Corps Program

Rolling Applications for Cohorts 5 & 6 for the newly rebranded Propelus I-Corps program, which is a 4-week regional I-Corps program for researchers to explore the commercial potential for their innovations through Customer Discovery. Accepted teams are awarded a $3,000 NSF grant which makes them eligible to get follow-on NSF funding.

https://icorpsnortheasthub.org/

Important NJ ACTS Resources for Clinical Research

RBHS Scientific Review Board for Non-Oncology and the System Enterprise-wide Expansion of the OnCore Clinical Trial Management System

The leadership and staff of the Rutgers IRB, the NJ ACTS Regulatory Core, and the RBHS Clinical Trials Office are announcing recent changes in the eIRB system that direct RBHS clinical investigators and their staff (non-oncology) to two new RBHS resources: the RBHS Scientific Review Board for Non-Oncology and the System Enterprise-wide expansion of the OnCore Clinical Trial Management System.

If your study fits certain parameters, you will be directed to submit it to the Scientific Review Board (SRB), the goal of which is to improve IRB submissions and thereby expedite the process for investigator-initiated studies. Additionally, certain studies will now use the OnCore Clinical Trial Management System, which interfaces with the eIRB and the EMRs, creating efficiencies.

For more information Read the Full Announcement

A Princeton Bioengineering Initiative

From Bench to Bedside:

Shifting Societal and Ethical Responsibilities for Bioengineers

Jodi Halpern MD, PhD - Chancellor’s Chair, Professor of Bioethics, UC Berkeley and Co-founder of the Berkeley Group on Ethics and Regulation of Innovative Technology will discuss how lab scientists are moving into translational research, often on an accelerated timeline.

Sep 27, 2022

4:00 pm – 5:30 pm

Friend Center Convocation Room, Princeton University

Visit Website to Read More

NJ ACTS in the News

Courtney McDermott Receives a

NIH NINDS F99/K00 Predoc to Postdoc Award

TL1 Predoctoral Trainee, Courtney McDermott has been award a Predoc to Postdoc award for her research on gut-microbiome-brain interactions in a novel gene x environment model of neurodevelopmental disorders. NJ ACTS congratulates Ms. McDermott and her mentors, Emanuel Dicicco-Bloom and Martin Blaser on this achievement. The award provides funding for the last 2 years of her PhD training and 4 years of her postdoc. Ms. McDermott is also the recipient of Society for Neuroscience, 2022 Trainee Professional Development Award through which she will receive complimentary registration to Neuroscience 2022 and associated travel costs.

Chintan Dave, PharmD, PhD

Congratulations to Chintan Dave, PharmD, PhD and colleagues on receipt of funding from the Juvenile Diabetes Research Foundation for the PREdictors for DiabetiC Ketoacidosis (DKA) at Diagnosisof Type 1 Diabetes (The PREDICT Study).

Chintan Dave, Assistant Professor at the Ernest Mario College of Pharmacy and former NJ ACTS KL2 Scholar, has received a three-year award for the largest and most comprehensive study of children at high risk of developing a life-threatening complication of Type 1 diabetes from JDRF, the leading global Type 1 diabetes research and advocacy organization. Joined by Sally Radovick, Jason Roy and Brian Strom, Dr. Dave will strive to identify risk factors associated with children who experience DKA and classify patients into risk categories to identify populations who may benefit from Type 1 diabetes screenings.

Read the Full Story

NJ ACTS Services

NJ ACTS Regulatory Knowledge and Support Topics

Regulatory and Operational Considerations for

Modernizing the Informed Consent Process

Electronic platforms hold potential to improve the informed consent (IC) process by incorporating graphics, self-pacing, meaningful engagement, and access to additional information on demand. These elements have been shown to increase research participant understanding and satisfaction.

Read the Full Article by NJ ACTS intern Isabel Parzecki

Funding Opportunity

New Jersey Health Foundation Annual Grant Program

New Jersey Health Foundation $2 Million Grant Program for Research (up to $35,000 each) or Community Health and Social Service (up to $25,000 each).

Sponsor deadline: November 7, 2022

NOTE for investigators: Proposals to NJHF are considered external and must be submitted through the institutional processes.

CTSA News and Events

From the Association for Clinical and Translational Science (ACTS)

Translational Science 2023 is looking for new ways to innovate translational science for research to create a scientific program that fosters inclusive conversations, furthers advancements in team science, and provides a platform for cutting-edge research.

Submissions are now open for poster and scientific session proposals!

Posters: research based posters eligible for a short oral platform presentation or poster presentation and published in JCTS.

Submit by November 14, 2022

Scientific Sessions: 60-minute concurrent scientific programming sessions organized as you wish and described in your session proposal.

Submit by October 24, 2022

Presentations will be in person in Washington, DC next year from April 19-21 with pre-meeting activities starting on April 18.

Building Your Team Science Toolbox

Professional Development Roundtable will address the following:

What specific competencies should scientists have to work well on teams?
What collaboration challenges have you experienced and how might these competencies help to address them?
How can we best assess and develop team science competencies?

September 21, 2022

2:00PM - 3:30PM

New from NCATS:

Translational Science Principles

The NCATS Translational Science Principles are a new resource that summarizes key approaches for accelerating progress along the translational pipeline toward solutions to improve human health. The principles complement the 2011 CTSA Education Core Competency Work Group’s 14 Core Competencies in Clinical and Translational Research.

NJ ACTS Publications

Demographic and Psychosocial Characteristics Associated With Use of a Prostate Cancer Survivorship Website: Implications From a Multisite Randomized Controlled Trial. Marziliano A, Diefenbach MA, Hudson SV, Tagai EK, Handorf EA, Bator A, Miller SM. J Med Internet Res. 2022 Mar 21;24(3):e27890. PMID: 35311678. PMCID: PMC8981019. DOI: 10.2196/27890 Clinical Trial.

Adolescent Chronic Health Conditions and School Disconnectedness . James C, Corman H, Noonan K, Reichman NE, Jimenez ME. J Dev Behav Pediatr. 2022 Feb-Mar 01;43(2):87-95. PMID:34191763. PMCID: PMC8714866. DOI:10.1097/DBP.0000000000000987.

Click Here for More NJ ACTS Publications